This company has been marked as potentially delisted and may not be actively trading. OncoMed Pharmaceuticals (OMED) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tenaya Therapeutics appoints new interim principal accounting officerFebruary 8, 2025 | msn.comIonis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, PredictionsJune 8, 2023 | benzinga.comBispecific Antibody Market Size | Statistics By 2031April 7, 2023 | marketwatch.com2023, Bispecific Antibody Market is thriving worldwide by 2029March 30, 2023 | marketwatch.com2023-2029 Cancer Stem Cell Market Size and Risks Factors Analysis | Survey Report by Absolute ReportsFebruary 28, 2023 | marketwatch.comForecast for 2028, Bispecific Antibody Market 2023, Global Industry Trends, Share, Size, Growth, DemandFebruary 27, 2023 | marketwatch.comBispecific Antibody Market : Top Key Players Data with Upcoming Opportunities and InnovationsFebruary 16, 2023 | marketwatch.comBispecific Antibody Market Insights-Industry changing aspects, New Technologies and Forecast to 2029February 4, 2023 | marketwatch.comBispecific Antibody Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook ReportJanuary 19, 2023 | marketwatch.comBispecific Antibody Market New Innovations and Future Expansion 2022-2028 with Top Countries DataNovember 18, 2022 | marketwatch.comFallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightNovember 14, 2022 | finance.yahoo.comImugene welcomes drug development, oncology and cell therapy expert to the teamSeptember 7, 2022 | au.investing.comShuttle Pharmaceuticals Shares Continue to Surge, Rising 74%September 1, 2022 | marketwatch.comShuttle Pharmaceuticals Shares More Than Triple in DebutAugust 31, 2022 | marketwatch.comClosing Bell: Stocks End Higher As Corporate Earnings Take FocusAugust 16, 2022 | thestreet.comBusiness of Pride: When social injustice calls, Nkarta answersJune 10, 2022 | bizjournals.comWorldwide Bispecific Antibody Market to 2028 - Ongoing Clinical Trials Assessment by Status, Phase, and RegionMay 25, 2022 | finance.yahoo.comInsights on the Bispecific Antibody Global Market - Approved Drug Sales Forecast Till 2028May 24, 2022 | finance.yahoo.comJim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into PanicApril 29, 2022 | thestreet.comAdenoid Cystic Carcinoma Pipeline is Indicative of Many Opportunities Left For Research and Development, Analyzes DelveInsightMarch 10, 2022 | finance.yahoo.comUS Cancer Antibodies Market 2028February 18, 2022 | uk.finance.yahoo.comCowden Syndrome Treatment Market Trending Report 2021| Size, Share, Status and Revenue and Future Predictions to 2027October 15, 2021 | marketwatch.comKuick Research: Global Bispecific Antibody Market Forecast Trends Sales Size Insight 2028October 6, 2021 | finanznachrichten.deGlobal Bispecific Antibody Market Forecast Trends Sales Size Insight 2028October 6, 2021 | prnewswire.comAdagio Therapeutics, Inc.: Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of DirectorsJuly 30, 2021 | finanznachrichten.deAdagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of DirectorsJuly 29, 2021 | finance.yahoo.com Get OncoMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Email Address OMED Media Mentions By Week OMED Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OMED News Sentiment▼0.000.72▲Average Medical News Sentiment OMED News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OMED Articles This Week▼00▲OMED Articles Average Week Get OncoMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NKTR News GLSI News SLS News THTX News LYEL News ENTA News RAPT News SCPH News CTNM News IMUX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OMED) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoMed Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.